REGN · NASDAQ · STOCK
Regeneron Pharmaceuticals (REGN) Stock Analysis
$746.88
52W $541.00 – $859.34
63/100
$76.91B
17.8
0.24
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is REGN Bullish or Bearish?
Bullish.
Innellis AI committee rates Regeneron Pharmaceuticals (REGN) Buy with a composite score of 63/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.53 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.47 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.09) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.09) -- balance sheet can absorb a shock — Risk
Bear Case
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
63/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 10%
of 192 Healthcare peers
Value Analyst
bullish
62
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
Growth Analyst
bullish
68
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.09) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 63.5 to 63.5.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
43.4
Neutral
MACD Histogram
-3.297
Bearish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$728.73
Resistance
$747.75
Bollinger %B
0.32
Inside Bands
Price vs Moving Averages
EMA 9
$746.91
Below
EMA 21
$762.56
Below
EMA 50
$763.40
Below
EMA 200
$726.93
Above
Fundamental Analysis
Valuation
58
Growth
79
Profitability
93
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
17.8×
P/B Ratio
2.43×
PEG Ratio
57.25
Dividend Yield
0.50%
52W High
$859.34
52W Low
$541.00
Quality & Growth
ROE
1441.2%
ROA
1110.7%
Gross Margin
8485.9%
Operating Margin
2555.6%
Revenue Growth YoY
—
Debt / Equity
0.06
AI Fundamental Assessment
P/E ratio of 17.8 (inexpensive relative to a 15-40x range); Price-to-book of 2.4x; PEG ratio of 57.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 14.4%; Return on assets of 11.1%; Net margin of 27.9%; Gross margin of 84.9%; Current ratio of 3.34 (healthy short-term liquidity); Debt-to-equity of 0.06; Free cash flow per share is positive (34.06); Most recent quarter beat estimates by 36.5%; 5 consecutive earnings beats; EPS growth accelerating (-17.2% -> +50.9% QoQ); Average YoY EPS growth of 10.9%; Analyst estimates falling over recent quarters
Get the Full REGN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →